Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00358826
Status:
COMPLETED
Last Update Posted:
2012-07-23
First Post:
2006-07-28
Brief Title:
Study Effect of VIA-2291 on Vascular Inflammation
Sponsor:
Tallikut Pharmaceuticals Inc
Organization:
Tallikut Pharmaceuticals Inc
Study Overview
Official Title:
Clinical Study Protocol No VIA-2291-01 A Phase 2 Randomized Double-blind Parallel-group Placebo-controlled Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a dose ranging study to compare the effect of VIA-2291 vs Placebo on various inflammatory biomarkers in patients with recent acute coronary events
Detailed Description:
This is a Phase II randomized double-blind placebo-controlled study of the effect of VIA-2291 on atherosclerotic vascular inflammation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None